On February 2, 2023 Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, reported that effective as of market open today, January 31, 2023, its common stock has been approved for uplisting to the Nasdaq Global Select Market and will continue trading under its current ticker symbol "DVAX" (Press release, Dynavax Technologies, JAN 31, 2023, View Source [SID1234626782]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dynavax’s advancement to the Nasdaq Global Select Market is a further outcome of continued excellence in execution across the organization, and reflective of our strong growth and financial performance in recent years," said Ryan Spencer, Chief Executive Officer of Dynavax. "The Nasdaq Global Select Market is recognized as having the highest listing standards of any exchange in the world. Dynavax is honored to be among this class of company. I want to thank our stakeholders, partners, patients and employees, as we work diligently to execute our growth strategy in continual pursuit of the corporate mission to help protect the world against infectious disease."

Dynavax was previously listed on the Nasdaq Capital Market. The Nasdaq Global Select Market consists of over 1,700 stocks that meet Nasdaq’s strictest financial and liquidity requirements and corporate governance standards.